T807

T807 is a tau-binding agent.¹ It selectively binds to recombinant tau (K_d = 0.2 and 16.8 nM for high- and low-affinity tau binding sites) over 83 receptors, transporters, enzymes, and ion channels in a panel at 10 µM but does bind to monoamine oxidase A (MAO-A) and MAO-B (K_ds = 1.6 and 21 nM, respectively). T807 binds to native tau fibrils from patients with Alzheimer’s disease or progressive supranuclear palsy (PSP; K_ds = 0.3 nM for both for high-affinity tau binding sites; K_ds = 30 and 70 nM, respectively, for low-affinity tau binding sites) but also binds to brain homogenates from patients without a tau-related disease (K_ds = 0.6 and 52.5 nM for high- and low-affinity tau binding sites, respectively) due to its off-target binding to MAO-A and MAO-B. A radiolabeled form of T807, ¹⁸F-T807, has been used in the imaging of tau in animal models of tau pathology in vivo and in postmortem human brain tissue from patients with Alzheimer’s disease.² 

WARNING This product is not for human or veterinary use.

1. Vermeiren, C., Motte, P., Viot, D., et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov. Disord. 33(2), 273-281 (2018).

2. Brendel, M., Yousefi, B.H., Blume, T., et al. Comparison of 18F-T807 and 18F-THK5117 PET in a mouse model of tau pathology. Front. Aging Neurosci. 10, 174 (2018).